# Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

> **NCT06473779** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 326 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **COMBINATION_PRODUCT:** Tezepelumab
- **COMBINATION_PRODUCT:** Budesonide/formoterol
- **COMBINATION_PRODUCT:** Albuterol/budesonide (AIRSUPRA®)
- **COMBINATION_PRODUCT:** Mannitol
- **COMBINATION_PRODUCT:** Salbutamol

## Key facts

- **NCT ID:** NCT06473779
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2027-06-25
- **Final completion:** 2027-06-25
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06473779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06473779, "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06473779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*